VB 10.2210
Alternative Names: VB10.2210Latest Information Update: 28 Sep 2022
Price :
$50 *
At a glance
- Originator Vaccibody
- Developer Nykode Therapeutics
- Class COVID-19 vaccines; DNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 27 Sep 2022 Interim immunogenicity and adverse events data from a phase I/II trial in COVID-2019 infections (Prevention) released by Nykode Therapeutics
- 23 Nov 2021 Vaccibody is now called Nykode Therapeutics
- 27 Oct 2021 Phase-I/II clinical trials in COVID-2019 infections (Prevention) in Norway (IM) (NCT05069623)